How Venom Peptides That Target a Pain Receptor Could Lead to New Painkillers | Research

The takeaway

Peptides from venomous animals can precisely target the outer pore of TRPV1, a major pain receptor, offering a new approach to designing non-opioid painkillers.

TRPV1 outer pore targeting
Venom peptides bind a specific region of the pain receptor that earlier synthetic drugs could not selectively target, offering a more precise approach to pain control

What the researchers found

Various peptides isolated from venomous animals (spiders, scorpions, and others) can potently and selectively bind to the outer pore region of the TRPV1 ion channel — a key pain receptor. These venom peptides can either activate or inhibit TRPV1, and their specificity for this particular region of the receptor makes them valuable templates for designing new pain medications.

TRPV1 is activated by multiple painful stimuli including heat, acid, and inflammatory chemicals, and contributes to both acute and chronic pain conditions. By targeting its outer pore rather than its ligand-binding site, venom peptides offer a mechanistically distinct approach to controlling pain signaling.

Why it matters

Chronic pain remains one of medicine's biggest challenges, and current treatments — particularly opioids — carry serious risks of addiction and overdose. TRPV1 has emerged as a promising non-opioid pain target, but early synthetic TRPV1 blockers caused dangerous side effects like loss of heat sensation. Venom-derived peptides that target a specific region of the receptor offer a potentially more selective approach, blocking pain without eliminating protective sensations. Nature's millions of years of venom evolution have produced highly precise molecular tools that drug developers are now learning to repurpose.

The numbers in context

TRPV1 outer pore region · multiple venom species · polymodal receptor activation (heat, acid, inflammation)

How the study worked

This is a narrative review examining published research on venom-derived peptide toxins that interact with the outer pore region of the TRPV1 ion channel. The authors analyzed the molecular mechanisms of peptide-receptor binding and discussed how these interactions could inform analgesic drug development.

Who was studied

Review of preclinical research on venom-derived peptides targeting TRPV1 for pain

What this study cannot tell us

As a review, this does not present new experimental data. The venom peptide research discussed is largely preclinical — most peptides described have not been tested in human clinical trials for pain. The translation from venom peptide to viable drug faces significant challenges including stability, delivery, and potential toxicity.

How to read the evidence

This is rated as a Review/Reference because it synthesizes existing preclinical research on venom peptides and TRPV1 without presenting new experimental data. The underlying studies are largely in vitro and animal-based.

When this study was published

Published in 2022, this review reflects recent understanding of venom peptide-TRPV1 interactions. The field of venom-derived analgesics continues to advance, with new peptide candidates being identified regularly.

The bigger picture

The search for non-opioid pain treatments is one of the most urgent priorities in drug development. Venom-derived peptides represent a growing class of drug candidates — ziconotide (from cone snail venom) is already FDA-approved for severe pain. This review highlights how the remarkable specificity of venom peptides for TRPV1's outer pore could overcome the selectivity problems that plagued earlier synthetic TRPV1 blockers, potentially enabling pain relief without the side effects that derailed previous approaches.

Questions still open

Can venom-derived TRPV1 peptides be modified for oral or injectable delivery while retaining their selectivity?
Would targeting the outer pore of TRPV1 avoid the dangerous loss of heat sensation seen with earlier TRPV1 antagonists?
Which specific venom peptides are closest to entering human clinical trials for pain?

Common questions

What is TRPV1 and why is it important for pain?

TRPV1 is a receptor on nerve endings that responds to painful stimuli like extreme heat, acid, and inflammatory chemicals — it's actually the receptor that makes chili peppers burn. Because it's a gateway for many types of pain signals, blocking it could potentially treat multiple pain conditions without using opioids.

Why use venom peptides instead of just making synthetic drugs?

Animal venoms have evolved over millions of years to precisely target specific receptors. Venom peptides can bind to very specific parts of pain receptors with a selectivity that synthetic drugs have struggled to achieve. Earlier synthetic TRPV1 blockers caused dangerous side effects because they weren't selective enough — venom peptides may solve this problem.

Read the original research

Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development.

International journal of molecular sciences, 23(10)

View on PubMed ↗Publisher’s paper ↗

Citation

Hwang, Sung-Min; Jo, Youn-Yi; Cohen, Cinder Faith; Kim, Yong-Ho; Berta, Temugin; Park, Chul-Kyu. (2022). Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development.. International journal of molecular sciences, 23(10). https://doi.org/10.3390/ijms23105772